- Autores: Amaral L, Martins M, Viveiros M
- Journal: Letters in Drug Design & Discovery
- Link: https://apps.webofknowledge.com/full_record.do?product=UA&search_mode=GeneralSearch&qid=15&SID=P2WA5hwy5j35Sqjoq2z&page=1&doc=1
Pulmonary tuberculosis infections caused by multi-drug resistant Mycobacterium tuberculosis has progressed to extensively drug resistant status (XDR-TB). XDR-TB is very difficult to treat successfully and results in high mortality. Globally, XDR-TB is now a major threat, especially to India and countries that were once part of the Soviet Union.
There is a potential alternative to current ineffective therapy that is solidly supported by in vitro, ex vivo and in vivo studies. It has reported successful therapies in 10 out of 12 non-responsive XDR-TB patients. That therapy is thioridazine, and it is the purpose of this mini-review to provide the rationale for thioridazine therapy, especially for compassionate reasons, when all other therapies have failed, depicting on extremely poor prognosis.